ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN MATCHED SIBLINGS

匹配兄弟姐妹的同种异体外周血干细胞移植

• 批准号: 6217287
• 负责人: FREDERICK APPELBAUM
• 金额: $ 34.64万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6217287
• 关键词: CD4 molecule; CD8 molecule; bone marrow transplantation; chronic myelogenous leukemia; clinical research; clinical trials; combination therapy; graft versus host disease; hematopoietic stem cells; histocompatibility typing; homologous transplantation; human subject; human therapy evaluation; leukemia; medical complication; neoplasm /cancer immunotherapy; siblings

The overall objective of this Project is to determine if the outcome of allogeneic transplantation for hematologic malignancies can be improved through the use of growth factor mobilized peripheral blood stem cells (PSBCs) instead of marrow. Initially, a prospective randomized trail will be performed in patients with a variety of hematologic malignancies undergoing transplantation from matched siblings in which the outcome using unmodified G-CSF mobilized PBSCs will be compared with that using marrow. If the results demonstrate that PBSCs lead to more rapid engraftment without a significant increase in graft-versus-host disease (GVHD), the trail will be continued in patients with a single hematologic malignancy, chronic myeloid leukemia. Additional studies will be carried out examining if the results of transplantation using PBSCs can be further improved by partial T cell depletion. Specifically, clinical studies will be conducted based on animal experiments demonstrating that engraftment without GVHD can be achieved with complete CD4 and partial CD8 depletion. The results of these studies should define the optimal stem cell product for use in matched sibling transplantation.

这个项目的总体目标是确定结果是否